“CD20×CD3 Bispecific Antibodies in Relapsed Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety”. Journal of Medical Sciences, vol. 21, no. 2, Sept. 2026, pp. 30-35, https://doi.org/10.51984/szn7cg42.